FWBI - Listing Plans on Adding by Streamlining

2023-12-27 07:49:33 ET

DENVER, Colo., Dec 27, 2023 ( www.247marketnews.com )- First Wave BioPharma, Inc. (NASDAQ: FWBI) stated, this morning, that it entered into a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases (IBD), which will enable First Wave BioPharma to focus its development resources on its three late-stage clinical programs: Capeserod, a selective 5-HT4 receptor partial agonist licensed from Sanofi; Adrulipase, a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency (EPI); and, after the closing of the recently announced potential business combination with ImmunogenX, Latiglutenase, a Phase 3-ready oral biotherapeutic for celiac disease.

First Wave BioPharma is trading at $6.55, up $2.86 (+77.99%), on 721.2K shares traded.

Its 52-week range is $2.75 to …

The post Listing Plans on Adding by Streamlining appeared first on 24/7 Market News .

For further details see: